NewAmsterdam Pharma Company N.V.
NAMSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, NewAmsterdam Pharma Company N.V. focuses on Biotechnology services and products. NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. The $2.97B market capitalization puts NAMS squarely in mid-cap range for its industry. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Market Cap
$2.97B
Beta
0.09
P/E (TTM)
—
P/E (Fwd)
-16.23
EPS (TTM)
$-2.16
EPS (Fwd)
$-1.56
ROE
-36.8%
ROA
-20.1%
Cash
$633.9M
Total Debt
$82,000
Free CF
-$45.4M
52W Change
1.2%
Annual Financials
Cash vs Debt
Where NAMS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NAMS finished 19.38% below its 150-day moving average ($31.74) and 21.72% below its 200-day moving average ($32.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NAMS overbought or oversold?
At the September 3, 2026 close, NAMS's RSI(14) was 42.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $633.9M in cash comfortably exceeding the $82K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$45.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -36.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $102.7M (2022) to $22.5M (2025), a 78% decline worth watching.
The relatively low beta of 0.09 suggests NAMS is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, NAMS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NAMS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.